Sarcoma treatment in the era of molecular medicine

Thomas G.P. Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E. Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L. Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M. Tomazou; Marcel Trautmann; Maria Vela; Yvonne M.H. Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J. Schober; Andrej Lissat; William R. English; Nicola Baldini; Dominique Heymann

doi:10.15252/emmm.201911131

Sarcoma treatment in the era of molecular medicine

Thomas G.P. Grünewald^*, Marta Alonso, Sofia Avnet, Ana Banito, Stefan Burdach, Florencia Cidre-Aranaz, Gemma Di Pompo, Martin Distel, Heathcliff Dorado-Garcia, Javier Garcia-Castro, Laura González-González, Agamemnon E. Grigoriadis, Merve Kasan, Christian Koelsche, Manuela Krumbholz, Fernando Lecanda, Silvia Lemma, Dario L. Longo, Claudia Madrigal-Esquivel, Álvaro Morales-MolinaJulian Musa, Shunya Ohmura, Benjamin Ory, Miguel Pereira-Silva, Francesca Perut, Rene Rodriguez, Carolin Seeling, Nada Al Shaaili, Shabnam Shaabani, Kristina Shiavone, Snehadri Sinha, Eleni M. Tomazou, Marcel Trautmann, Maria Vela, Yvonne M.H. Versleijen-Jonkers, Julia Visgauss, Marta Zalacain, Sebastian J. Schober, Andrej Lissat, William R. English, Nicola Baldini, Dominique Heymann

^*Corresponding author for this work

Centre for Craniofacial & Regenerative Biology

Research output: Contribution to journal › Review article › peer-review

157 Citations (Scopus)

Abstract

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.

Original language	English
Article number	e11131
Journal	EMBO Molecular Medicine
Volume	12
Issue number	11
DOIs	https://doi.org/10.15252/emmm.201911131
Publication status	Published - 6 Nov 2020

Keywords

bone sarcoma
molecular diagnostics
molecular medicine
soft tissue sarcoma
targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.15252/emmm.201911131

Cite this

Grünewald, T. G. P., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre-Aranaz, F., Di Pompo, G., Distel, M., Dorado-Garcia, H., Garcia-Castro, J., González-González, L., Grigoriadis, A. E., Kasan, M., Koelsche, C., Krumbholz, M., Lecanda, F., Lemma, S., Longo, D. L., Madrigal-Esquivel, C., ... Heymann, D. (2020). Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 12(11), Article e11131. https://doi.org/10.15252/emmm.201911131

@article{0822128dc58b46adb3957f0ab3e66fd5,

title = "Sarcoma treatment in the era of molecular medicine",

abstract = "Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.",

keywords = "bone sarcoma, molecular diagnostics, molecular medicine, soft tissue sarcoma, targeted therapy",

author = "Gr{\"u}newald, {Thomas G.P.} and Marta Alonso and Sofia Avnet and Ana Banito and Stefan Burdach and Florencia Cidre-Aranaz and {Di Pompo}, Gemma and Martin Distel and Heathcliff Dorado-Garcia and Javier Garcia-Castro and Laura Gonz{\'a}lez-Gonz{\'a}lez and Grigoriadis, {Agamemnon E.} and Merve Kasan and Christian Koelsche and Manuela Krumbholz and Fernando Lecanda and Silvia Lemma and Longo, {Dario L.} and Claudia Madrigal-Esquivel and {\'A}lvaro Morales-Molina and Julian Musa and Shunya Ohmura and Benjamin Ory and Miguel Pereira-Silva and Francesca Perut and Rene Rodriguez and Carolin Seeling and {Al Shaaili}, Nada and Shabnam Shaabani and Kristina Shiavone and Snehadri Sinha and Tomazou, {Eleni M.} and Marcel Trautmann and Maria Vela and Versleijen-Jonkers, {Yvonne M.H.} and Julia Visgauss and Marta Zalacain and Schober, {Sebastian J.} and Andrej Lissat and English, {William R.} and Nicola Baldini and Dominique Heymann",

year = "2020",

month = nov,

day = "6",

doi = "10.15252/emmm.201911131",

language = "English",

volume = "12",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

publisher = "Wiley-Blackwell",

number = "11",

}

Grünewald, TGP, Alonso, M, Avnet, S, Banito, A, Burdach, S, Cidre-Aranaz, F, Di Pompo, G, Distel, M, Dorado-Garcia, H, Garcia-Castro, J, González-González, L, Grigoriadis, AE, Kasan, M, Koelsche, C, Krumbholz, M, Lecanda, F, Lemma, S, Longo, DL, Madrigal-Esquivel, C, Morales-Molina, Á, Musa, J, Ohmura, S, Ory, B, Pereira-Silva, M, Perut, F, Rodriguez, R, Seeling, C, Al Shaaili, N, Shaabani, S, Shiavone, K, Sinha, S, Tomazou, EM, Trautmann, M, Vela, M, Versleijen-Jonkers, YMH, Visgauss, J, Zalacain, M, Schober, SJ, Lissat, A, English, WR, Baldini, N & Heymann, D 2020, 'Sarcoma treatment in the era of molecular medicine', EMBO Molecular Medicine, vol. 12, no. 11, e11131. https://doi.org/10.15252/emmm.201911131

TY - JOUR

T1 - Sarcoma treatment in the era of molecular medicine

AU - Grünewald, Thomas G.P.

AU - Alonso, Marta

AU - Avnet, Sofia

AU - Banito, Ana

AU - Burdach, Stefan

AU - Cidre-Aranaz, Florencia

AU - Di Pompo, Gemma

AU - Distel, Martin

AU - Dorado-Garcia, Heathcliff

AU - Garcia-Castro, Javier

AU - González-González, Laura

AU - Grigoriadis, Agamemnon E.

AU - Kasan, Merve

AU - Koelsche, Christian

AU - Krumbholz, Manuela

AU - Lecanda, Fernando

AU - Lemma, Silvia

AU - Longo, Dario L.

AU - Madrigal-Esquivel, Claudia

AU - Morales-Molina, Álvaro

AU - Musa, Julian

AU - Ohmura, Shunya

AU - Ory, Benjamin

AU - Pereira-Silva, Miguel

AU - Perut, Francesca

AU - Rodriguez, Rene

AU - Seeling, Carolin

AU - Al Shaaili, Nada

AU - Shaabani, Shabnam

AU - Shiavone, Kristina

AU - Sinha, Snehadri

AU - Tomazou, Eleni M.

AU - Trautmann, Marcel

AU - Vela, Maria

AU - Versleijen-Jonkers, Yvonne M.H.

AU - Visgauss, Julia

AU - Zalacain, Marta

AU - Schober, Sebastian J.

AU - Lissat, Andrej

AU - English, William R.

AU - Baldini, Nicola

AU - Heymann, Dominique

PY - 2020/11/6

Y1 - 2020/11/6

N2 - Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.

AB - Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.

KW - bone sarcoma

KW - molecular diagnostics

KW - molecular medicine

KW - soft tissue sarcoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85092390651&partnerID=8YFLogxK

U2 - 10.15252/emmm.201911131

DO - 10.15252/emmm.201911131

M3 - Review article

AN - SCOPUS:85092390651

SN - 1757-4676

VL - 12

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 11

M1 - e11131

ER -

Sarcoma treatment in the era of molecular medicine

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this